Parean Biotechnologies is officially partner and consortium member, of Horus Project ! This new approved 7+ Million Euros project, funded by... View Article
Author Archives for Adeline Chauvigné
Transplantation & immunology | Parean Biotechnologies joins a European consortium funded by Horizon Europe
6 July 2025Parean Biotechnologies is officially partner and consortium member, of Horus Project ! This new approved 7+ Million Euros project, funded by... View Article
New member | SIB
Leading digital cooperative actor serving the public sector, the French public benefit corporation SIB is an expert in conception, deployment,... View Article
New member | SIB
6 July 2025Leading digital cooperative actor serving the public sector, the French public benefit corporation SIB is an expert in conception, deployment,... View Article
New member | BA Healthcare
BA Healthcare, a company based in Rennes and created in 2011, specializes in the design and mass production of medical... View Article
New member | BA Healthcare
6 July 2025BA Healthcare, a company based in Rennes and created in 2011, specializes in the design and mass production of medical... View Article
Cluster-to-business knowledge transfer
To strengthen SMEs and start-ups from partnering clusters, the Pitch Coaching Training was organised to expose SMEs to the specific... View Article
Cluster-to-business knowledge transfer
6 July 2025To strengthen SMEs and start-ups from partnering clusters, the Pitch Coaching Training was organised to expose SMEs to the specific... View Article
Transnational missions (C2C exchanges)
The CE4BIG project (Cluster Excellence for Business, Innovation and Growth in the health sector), supported by the EU COSME Programme,... View Article
Transnational missions (C2C exchanges)
6 July 2025The CE4BIG project (Cluster Excellence for Business, Innovation and Growth in the health sector), supported by the EU COSME Programme,... View Article
InFlectis BioScience granted Orphan Drug Designation for IFB-088 (icerguastat), a clinical stage treatment for Amyotrophic Lateral Sclerosis
IFB-088 has been granted Orphan-Drug Designation from the FDA in the treatment of Amyotrophic Lateral Sclerosis (ALS). IFB-088 is a... View Article
InFlectis BioScience granted Orphan Drug Designation for IFB-088 (icerguastat), a clinical stage treatment for Amyotrophic Lateral Sclerosis
6 July 2025IFB-088 has been granted Orphan-Drug Designation from the FDA in the treatment of Amyotrophic Lateral Sclerosis (ALS). IFB-088 is a... View Article
Promega Corporation and FUJIFILM Cellular Dynamics announce strategic collaboration to advance novel assay development
New licensing agreement will deliver luminescent reporter technology into iPSCs Promega Corporation (Promega), a leader in providing innovative solutions and technical... View Article
Promega Corporation and FUJIFILM Cellular Dynamics announce strategic collaboration to advance novel assay development
6 July 2025New licensing agreement will deliver luminescent reporter technology into iPSCs Promega Corporation (Promega), a leader in providing innovative solutions and technical... View Article
Pherecydes Pharma granted a new patent for its anti-Pseudomonas aeruginosa phages in Europe
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the... View Article
Pherecydes Pharma granted a new patent for its anti-Pseudomonas aeruginosa phages in Europe
6 July 2025Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the... View Article
OSE Immunotherapeutics provides positive long term memory responses with CoVepiT, its T lymphocyte multi-target anti-COVID vaccine
Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.... View Article
OSE Immunotherapeutics provides positive long term memory responses with CoVepiT, its T lymphocyte multi-target anti-COVID vaccine
6 July 2025Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.... View Article
SEABELIFE RECEIVES CLOSE TO €1.4M DEEP TECH FINANCING FROM BPIFRANCE
Funds will enable SeaBeLife to develop pipeline of innovative molecules intended to block programmed cell death in cases of acute... View Article
SEABELIFE RECEIVES CLOSE TO €1.4M DEEP TECH FINANCING FROM BPIFRANCE
6 July 2025Funds will enable SeaBeLife to develop pipeline of innovative molecules intended to block programmed cell death in cases of acute... View Article